Research, Report & Profiling Services by IPOdesktop.com

BioTech Medics, Inc. Stock symbol: BTMD.PK………….………………..Ave daily volume: 232,000; Float: 19mm Stock price 2/1/05: $.05………………..…Outstanding Common shares: 2/1/05: 115 million

52-week price range: $.01 - 0.50…………………Equity market capitalization: $5.75 million

Recent News…..Stock Price…..Chart…..SEC Filings

Listen to the Interview with Keith Houser, CEO February 02, 2005

HIGHLIGHTS

BTMD offers safe drug & surgery free alternative pain management & wellness products

BTMD is marketing an FDA-510(k)approved Medical laser device

For the safe, drug & surgery-free alternative treatment for pain management.

The NeuroLase is also an excellent Vioxx/Celebrex substitute for arthritis pain management.

The Company plans on rolling out two other patented health products later this year.

BTMD pain treatment centers, based on the 'healing laser' & alternative healthcare

BTMD plans on covering 60% of the U.S. population with 75 -100 pain management centers

The NeuroLase & it’s prototype has undergone 8 years R&D

BTMD has it’s first managed operating Dallas, TX Pain Treatment Center open & expects to generate $1.5 million in revenue this year

RECENT DEVELOPMENTS

Laser Therapeutics of Albuquerque, New Mexico has acquired a NeuroLase Medical Laser from BioTech Medics. Another med practice in Palm Beach County, FL has a sale pending.

These will be part of the first of 75-100 Pain Management & Wellness Centers across the USA offering the NeuroLase," according to BTMD's CEO.

-----------------------------------------------------------------------

Address: 222 W. Las Colinas Blvd., Suite 1650E, Irving, TX 75039 Telephone: 972-274-5533 CEO: Keith Houser

Web Site: www.biotechmedics.com

State or other jurisdiction of incorporation or organization: Nevada

Auditors: Bagell, Josephs & Company, LLC Transfer Agent: First Global Stock Transfer, Las Vegas, NV

Investor contact: Keith Houser 972-274-5533, khouser@biotechmedics.com

-----------------------------------------------------------------------

PAIN MANAGEMENT: A $32 BILLION ANNUAL REVENUE INDUSTRY

Over 150 million Americans are in pain daily according to the Center for Disease Control

The aging of Americans with pain has placed a demand upon medical practitioners

BTMD has a competitive advantage in the market to be able to provide a quick, safe means of treating over 50 types of pain in patients without unnecessary surgery or drugs

PRODUCT

The NeuroLase™ 150 Medical Laser

Is the only known published approved Low Level Light Laser in the USA for use on the entire body with a 15 watt diode

Is manufactured in the USA

What it does

The NeuroLase may

Temporarily increase blood circulation, and to promote relaxation of muscle tissue.

Be used for "minor pain and stiffness associated with arthritis or muscle spasm."

According to patients who have been treated with the laser: you can feel the natural healing of light as the laser moves across the area of your pain!

Applications

For various human physical ailments such as arthritis, carpal tunnel syndrome, backache, sprained ankle, shoulder and neck stiffness, whiplash, tennis elbow, a pulled muscle, TMJ, and 40 other ailments.

How it works

The NeuroLase device emits light energy in the infrared spectrum

Provides topical heating for temporary relief of minor muscle and joint pain and stiffness, minor arthritis pain, or muscle spasm.

Competition

Competitor lasers with significantly lower output wattage have been approved

For limited single use on one or two small areas of the body.

Sales

BTMD’s projected income is to be derived from 1) its primary distributorship for the NeuroLase medical device 2) Managing or operating Pain Management & Wellness Centers, 3) Acquiring and selling patented gingivitis and body detoxification products, 4) Training and Certifying medical professionals to be certified to operate the laser

The NeuroLase will only be sold to licensed medical practitioners or medical facilities in USA

NeuroLase History

Over 8 years in research and development have already been spent on the development and design of NeuroLase Medical Laser system.

The NeuroLase’s Patented proprietary technology covers an array of wavelength spectrum (frequency) for the low light level laser (LLLL) over its competition.

GROWTH PLAN FOR PAIN MANAGEMENT & WELLNESS CENTERS 75 to 100 (proposed) centers

Will combine blood testing, nutrition education and exercise instruction

To offer preventative medicine to help each patient regain their strength, and well-being

Offer alternative proprietary health products to help keep a person healthy

Roll-out plan

In the top 30 markets in the USA over the next 24-36 months

Covering over 60% of the US population.

BTMD has entered into Letters of Intent to acquire other patented proprietary products for gingivitis and body detoxification & cleansing

MANAGEMENT TEAM KEITH A. HOUSER, Age 56, Chairman & CEO BTMD. Mr. Houser brings a well-diversified experience as an entrepreneur as well as officer/director of several companies. Mr. Houser holds a B.A. degree from Malone College & has taken master degree graduate studies at Hamma School-Wittenberg University & ELTS-Capital University & is a graduate of CFNI, Dallas. He has taken continuing education courses at the University of Texas Southwestern Medical Center, Dallas. As a "Director" approved by the Texas Dept. of Health of SeniorPlus Adult Day Care in Dallas County, Texas, Mr. Houser worked daily with numerous licensed physicians, chiropractors, registered nurses, dieticians and therapists in caring for thousands of patient day visits. Mr. Houser has an extensive broadcasting background. He was an Advisor to Financial News Network ("FNN") now CNBC during FNN’s IPO in the early 1980’s. He marketed the LASIK eye surgery procedure in the 90’s for an Arlington ophthalmologist for the correction of nearsightedness. As an entrepreneur, he has founded two start-up companies, both of which currently have estimated values in excess of $200 million each. Mr. Houser has been on 3 philanthropic boards for over 30 years giving millions to the poor and underprivileged and to foreign Christian missionary projects in Mexico, the Philippines, Rwanda and Ecuador.

CHARLES R. CRANE, MD, Age 66, President of BTMD and Medical Director Is a private practice physician, with medical board specialization in physical Medicine & Rehabilitation and Electrodiagnostic Medicine. Dr. Crane is a Medical Consultant for Allied Medical Consultants; Physician Advisor to CENTRA Healthcare; Intracorp Medical Review; Concentra Healthcare; Medical Review; Texas Workers Compensation Fund; Texas Medical Foundation, PRO. KIM PERALTA JACOBS, D.C., F.A.S.A. Age 41, Secretary of BTMD. Dr. Jacobs is a graduate of Cleveland Chiropractic College, Kansas City, MO. She is a graduate of Park College, Parkville, MO, with a B.S. in nutrition (Cum Laude), and attended Donnelly College, Kansas City, KS, as a Pre-Med Student. Dr. Jacobs has her practice in Overland Park, KS.

ROBERT B. HONIGSFELD, DC, Age 56, BTMD Chiropractic Advisory Board Member, Is a private practice chiropractor in Dallas, Texas. He is the immediate Past-President of the American Board of Chiropractic Consultants (Jan.2003 to present), and President of the Board between January, 2000 and December, 2002. He is certified and commissioned State Licensing Examination Proctor for the Texas Board of Chiropractic Examiners, Diplomate for the American Board of Quality Assurance and Utilization Review Physicians since 1993; Diplomate for the American Board of Chiropractic Consultants, since 1990; Diplomate for the American Board of Chiropractic Orthopedist, 1987. Brenda Sewell, R.N., M.S., H.Ed. Advisory Board Member

Ms. Sewell is a graduate of Texas Woman’s University, with a B.S. in Nursing. She received her M.S in Health Education at the University of N. Texas, Denton. She is certified by the Texas Board of Nurse Examiners as a Registered Nurse. She is a lifetime Charter Member of the Sigma Theta Tau: Beta Beta Chapter of the National Honor Society for Nurses.

POdesktop (ID) SAFE HARBOR STATEMENT: Statements contained in this document, including those pertaining to estimates and related plans, potential mergers and acquisitions, estimates, growth, establishing new markets, expansion into new markets and related plans other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. ID provides no assurance as to the subject company's plans or ability to effect any planned and/or proposed actions. ID has no first-hand knowledge of management and therefore cannot comment on its capabilities, intent, resources, nor experience and makes no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company or its agent and related sources believed by ID to be reliable, but ID provides no assurance, and none is given, as to the accuracy and completeness of this information. DISCLAIMER: The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. ID has been compensated one thousand five hundred dollars from the company for preparation and posting of this report, radio interview, and other advertising services. This constitutes a conflict of interest as to ID’s ability to remain objective in its communication regarding the subject company. Analysts, principals, associates and employees of ID do not own or trade equities under coverage. For detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 contact IPOdesktop, 11693 San Vicente Blvd., #350, Los Angeles, CA 90049. ID is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement. Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results. The opinions contained herein reflect our current judgment and are subject to change without notice. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at http://www.sec.gov and the National Association of Securities Dealers (NASD) at http://www.nasd.com. The NASD has published information on how to invest carefully at its web site. Readers can review all public filings by companies at the SEC's EDGAR page.